Grace Makari-Judson to Treatment Outcome
This is a "connection" page, showing publications Grace Makari-Judson has written about Treatment Outcome.
Connection Strength
0.047
-
Viskochil R, Blankenship JM, Makari-Judson G, Staudenmayer J, Freedson PS, Hankinson SE, Braun B. Metrics of Diabetes Risk Are Only Minimally Improved by Exercise Training in Postmenopausal Breast Cancer Survivors. J Clin Endocrinol Metab. 2020 05 01; 105(5).
Score: 0.020
-
Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 2013 May 15; 19(10):2745-54.
Score: 0.012
-
Frank LS, Frank JL, March D, Makari-Judson G, Barham RB, Mertens WC. Does therapeutic touch ease the discomfort or distress of patients undergoing stereotactic core breast biopsy? A randomized clinical trial. Pain Med. 2007 Jul-Aug; 8(5):419-24.
Score: 0.008
-
Reuben SS, Makari-Judson G, Lurie SD. Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. J Pain Symptom Manage. 2004 Feb; 27(2):133-9.
Score: 0.007